国产黄片大全在线播放_多毛中国农村熟女吟呻对白_欧洲乱码在线播放_亚洲五月婷婷久久综合色

熱門搜索:A549    293T 金黃色葡萄球菌 大腸桿菌 AKK菌
購(gòu)物車 1 種商品 - 共0元
當(dāng)前位置: 首頁(yè) > ATCC代理 > CLNH5.5
最近瀏覽歷史
聯(lián)系我們
  • 0574-87157013
  • mingzhoubio@163.com
  • 浙江省寧波市鎮(zhèn)海區(qū)莊市街道興莊路9號(hào)
  • 創(chuàng)e慧谷42號(hào)樓B幢401室
CLNH5.5
CLNH5.5
規(guī)格:
貨期:
編號(hào):B164269
品牌:Mingzhoubio

標(biāo)準(zhǔn)菌株
定量菌液
DNA
RNA

規(guī)格:
凍干粉
斜面
甘油
平板


產(chǎn)品名稱 CLNH5.5
商品貨號(hào) B164269
Organism human (B cell); human (myeloma)
Tissue cervix
Cell Type hybridoma: B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2  [Cells contain Epstein-Barr virus]

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease squamous cell carcinoma
Applications
The antibody reacted with cell lines derived from carcinomas of the cervix (CaSki, HeLa), lung (T293H, Calu-1 and SK-MES-1), prostate (LnCap), vulva (A431), and melanoma (SK-MEL-28).
The antibody was negative for normal fibroblasts, T lymphocytes and peripheral blood lymphocytes.
The antibody may be useful in therapy and diagnosis, both in vitro and in vivo.
Storage Conditions liquid nitrogen vapor phase
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Derivation
Lymphocytes were isolated from a regional draining lymph node of a patient with squamous cell carcinoma of the cervix.
B lymphocytes were fused with UC 729-6 cells (see ATCC CRL-8061).
The antibody reacted with cell lines derived from carcinomas of the cervix (CaSki, HeLa), lung (T293H, Calu-1 and SK-MES-1), prostate (LnCap), vulva (A431), and melanoma (SK-MEL-28).
Clinical Data
Lymphocytes were isolated from a regional draining lymph node of a patient with squamous cell carcinoma of the cervix.
The antibody may be useful in therapy and diagnosis, both in vitro and in vivo.
Genes Expressed
immunoglobulin; monoclonal antibody; against human cervical carcinoma
Cellular Products
immunoglobulin; monoclonal antibody; against human cervical carcinoma
Comments
The fusion line, CRL-8061, is reported to be EBNA positive.
Lymphocytes were isolated from a regional draining lymph node of a patient with squamous cell carcinoma of the cervix.
B lymphocytes were fused with UC 729-6 cells (see ATCC CRL-8061).
The antibody reacted with cell lines derived from carcinomas of the cervix (CaSki, HeLa), lung (T293H, Calu-1 and SK-MES-1), prostate (LnCap), vulva (A431), and melanoma (SK-MEL-28).
The antibody was negative for normal fibroblasts, T lymphocytes and peripheral blood lymphocytes.
The antibody may be useful in therapy and diagnosis, both in vitro and in vivo.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
Subculturing
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10(5) viable cells/ml. Maintain cell density between 1 X 10(5) and 1 X 10(6) viable cells/ml.
Medium Renewal: Every 2 to 3 days
Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Temperature: 37.0°C
Isotype IgM
Name of Depositor HH Handley, Regents of the University of California
Deposited As human (B cell); human (myeloma)
U.S. Patent Number
References

Handley HH, et al. Methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies. US Patent 6,051,387 dated Apr 18 2000

Handley HH, et al. Human-human hybridom for neoplasms CLNH5 and CLNH11 specific antibody compositions. US Patent 6,051,229 dated Apr 18 2000

Handley HH, et al. Human-Human CLNH5-specific antibodies. US Patent 6,090,924 dated Jul 18 2000

Glassy MC, et al. Genetically stable human hybridomas secreting tumor-reactive human monoclonal IgM. Cancer Invest. 5: 449-457, 1987. PubMed: 3501329

梅經(jīng)理 17280875617 1438578920
胡經(jīng)理 13345964880 2438244627
周經(jīng)理 17757487661 1296385441
于經(jīng)理 18067160830 2088210172
沈經(jīng)理 19548299266 2662369050
李經(jīng)理 13626845108 972239479